This post was originally published on this site

[unable to retrieve full-text content]WALTHAM, Mass.–(BUSINESS WIRE)– ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised …